Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
European Urology|February 25, 2022
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 TrialSumanta K Pal, Javier Puente, Daniel Y C Heng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialFunda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.Cancer Control : Journal of the Moffitt Cancer Center|May 14, 2026
Multicenter Prospective Phase II Study of Induction Therapy With Pembrolizumab, Cisplatin, and Fluorouracil in Patients With Locally Advanced Head and Neck CancerIlya Pokataev, Olesia Stativko, Margarita Nosova, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCMark A Socinski, Makoto Nishio, Robert M Jotte, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.The New England Journal of Medicine|September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaJames Larkin, Paolo A Ascierto, Brigitte Dréno, et al.JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM StudyPaolo A Ascierto, Brigitte Dréno, James Larkin, et al.The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.Pageof 5